Long before cannabis became synonymous with prohibition, counterculture, dispensaries, or the modern medical-marijuana debate, it occupied an ordinary place inside American pharmacy. Major pharmaceutical houses manufactured cannabis tinctures and extracts alongside hundreds of other botanical medicines, and two companies that became particularly important to this history were Parke, Davis & Company of Detroit and Eli Lilly and Company of Indianapolis. The surviving bottles are striking today precisely because there is nothing clandestine about them. They look like what they were: commercial pharmaceutical products manufactured by companies attempting to build reputations around quality and consistency.

Cannabis had entered the United States Pharmacopeia in 1851 after Western medical interest in Indian hemp expanded during the first half of the nineteenth century. Physicians experimented with preparations for pain, sleep, spasms, and other conditions according to the medical thinking of their own period. Those historical uses should not be treated as modern recommendations, but they establish something important about the chronology: pharmaceutical cannabis was already well established before Colonel Eli Lilly opened his Indianapolis laboratory in 1876.

The more interesting question is what happened when a nineteenth-century herbal medicine encountered the emerging American pharmaceutical corporation. Companies such as Lilly and Parke-Davis did not merely want cannabis that worked sometimes. They wanted material that behaved consistently enough to be manufactured at scale, prescribed with confidence, and sold under a corporate name. Cannabis therefore became part of a much larger transformation in which American drug manufacturers attempted to turn the variability of living plants into standardized pharmaceutical products.

Colonel Lilly and the New Drug Manufacturer

Colonel Eli Lilly founded his company in Indianapolis in May 1876 after serving in the Union Army during the Civil War and working in the drug business. His original Pearl Street laboratory was tiny compared with the enormous company that later carried his name. The Indiana Historical Society describes the business as a wholesale drug-manufacturing operation established during a period when American pharmacy was changing rapidly, and the surviving image of the Pearl Street building makes the company’s origins look almost improbably modest.

That timing matters. Lilly entered the business while American pharmacy still depended heavily on crude botanical drugs, individual pharmacists, imported ingredients, and preparations whose potency could vary considerably. Large-scale pharmaceutical manufacturing promised something different: the same company’s bottle should mean roughly the same thing whether it reached a physician in Indiana, New York, or Missouri.

Cannabis exposed the difficulty of making that promise. Unlike a purified chemical compound, a medicinal plant could vary according to genetics, growing conditions, harvesting, storage, age, and processing. Imported shipments could also deteriorate or arrive with varying potency. The problem facing manufacturers therefore began before the drug ever entered the factory.

The Field Becomes Part of the Laboratory

Early pharmaceutical research consequently looked much more agricultural than most people imagine. A manufacturer attempting to control botanical medicines had an incentive to cultivate medicinal plants itself, compare varieties, and determine whether useful traits could be reproduced from one crop to the next. Lilly eventually operated experimental cultivation programs for precisely this reason.

The company’s own Hand Book of Pharmacy and Therapeutics from around 1919 contains remarkable color images of its experimental farm. Rows of henbane appear beside workers harvesting digitalis, while other surviving images document belladonna cultivation. The Science History Institute notes that Lilly used the experimental farm in an attempt to propagate medicinal plants as potent as imported European material.

This is the larger industrial setting in which the cannabis story makes sense. If the strength of a medicine depended upon a plant, control of medicine increasingly meant control of cultivation. The pharmaceutical laboratory expanded outward into greenhouses, test plots, farms, seed selection, and biological experimentation.

That logic eventually reached cannabis.

The Problem of Cannabis Indica

Much nineteenth-century Western medical literature treated potent medicinal cannabis as an imported substance associated especially with India. The terminology itself reinforced the geography: Cannabis indica became a familiar pharmaceutical designation, reflecting the importance of British imperial medicine and figures such as William Brooke O’Shaughnessy in introducing Indian cannabis preparations to Western physicians.

Importing medicinal plants presented an obvious industrial problem, however. The American manufacturer was separated from the crop by growers, brokers, shipping companies, merchants, weather, storage, and time. Even if one shipment proved excellent, the next might not.

The question that companies such as Parke-Davis and Lilly eventually asked was therefore deceptively simple: did medicinal cannabis really have to come from India?

The Smithsonian’s National Museum of American History preserves unusually strong evidence of the resulting experiment. Its Cannabis Americana collection records that in the late 1890s Eli Lilly and Company joined Parke-Davis in breeding cannabis in the United States. Parke-Davis promoted the resulting material as a “new and potent strain of domestic Cannabis,” while its surviving product label stated that the cannabis used for its American fluid extract was grown in the company’s own botanical gardens.

That is the real significance of Cannabis Americana. It was not simply imported cannabis poured into an American bottle. It represented an attempt to bring the plant itself inside the domestic pharmaceutical production system.

An American Cannabis Industry Before Prohibition

Parke-Davis advertisements make the ambition unusually explicit. One surviving advertisement promoted its fluid extract of Cannabis Americana as being as active as Indian cannabis and emphasized that physiological standardization could provide greater uniformity. The message was aimed directly at physicians who had reason to distrust variable botanical preparations.

This was a surprisingly modern sales argument. The company was not saying merely that American cannabis was cheaper or more patriotic. It was saying that domestic cultivation combined with pharmacological testing could potentially create a more dependable pharmaceutical commodity.

The Smithsonian record ties Eli Lilly directly to the late-1890s breeding effort, while Parke-Davis left particularly strong documentation of the cultivation and standardization side. That distinction is worth preserving. The evidence does not justify pretending that Lilly and Parke-Davis were one operation or that every surviving Parke-Davis cannabis field was a Lilly project, but the firms clearly participated in the same broader attempt to develop reliable American medicinal cannabis.

The Parke-Davis Laboratory

Parke-Davis itself had become an enormous pharmaceutical enterprise in Detroit. Its factory complex and research laboratories reveal the scale at which companies were beginning to approach drug production by the turn of the twentieth century. Cannabis was being pulled from the world of the herbal merchant into institutions that increasingly resembled modern research organizations.

The industrial landscape matters because Cannabis Americana was not being developed in isolation. Parke-Davis worked on numerous substances whose biological potency created standardization problems, and cannabis became one example of a broader pharmaceutical ambition. Companies wanted methods that could transform variable natural products into preparations whose effects could be predicted.

This culminated in one of the most revealing titles in cannabis history. In 1908 E. M. Houghton and H. C. Hamilton published A Pharmacological Study of Cannabis Americana: A Step in Standardizing Drugs. The subtitle is arguably more important than the cannabis itself, because it identifies the project as part of the new science of drug standardization rather than as an eccentric side experiment.

How Do You Measure Cannabis Before THC?

The researchers faced a problem that modern laboratories do not. They could not simply analyze a plant and receive a cannabinoid profile measuring THC, CBD, and other compounds. The relevant cannabinoid chemistry had not yet been worked out.

Consequently, pharmaceutical companies relied in part upon physiological assays. Instead of measuring an isolated active compound directly, investigators compared how different preparations acted biologically. Cannabis could be tested against a reference preparation to determine whether a new extract appeared weaker, stronger, or comparable.

The methods could involve animals, including dogs, whose coordination and other reactions were observed after administration. Such experiments belong to a very different ethical and scientific period, but conceptually the objective is easy to recognize: researchers wanted the next batch of cannabis extract to behave like the batch that had already been accepted as a standard.

That was an enormous change from simply receiving a bale or shipment of medicinal plant material and trusting its geographic label.

Lilly Was Selling Cannabis Under Its Own Name

Eli Lilly and Company also manufactured its own cannabis preparations, and the surviving bottle is one of the best images in the entire history. The label identifies Fluid Extract No. 96 — Cannabis, U.S.P., gives the botanical name Cannabis sativa, notes the alcohol content, and places the Lilly name underneath.

Nothing about the bottle suggests an illicit market. It belongs visually to the same pharmaceutical world as digitalis, belladonna, quinine, morphine preparations, and the hundreds of other drugs found in medical catalogs of the period. The striking thing to a modern viewer is precisely how ordinary it looks.

That ordinary appearance is historically valuable. It reminds us that the familiar twentieth-century distinction between “pharmaceutical drugs” and “marijuana” had not yet hardened into the form later generations inherited. Lilly’s product language was pharmacopoeial: cannabis, Cannabis U.S.P., fluid extract, dosage, alcohol percentage, and manufacturer.

Lilly’s 1919 Pharmaceutical World

The company’s 1919 Hand Book of Pharmacy and Therapeutics offers an extraordinary visual tour of the pharmaceutical system surrounding these products. The volume itself survives in the Science History Institute and Library of Congress collections and contains hundreds of pages of medicines, therapeutic information, buildings, equipment, cultivation, laboratories, stables, and manufacturing processes. The Science History Institute has made the material available as a public-domain collection.

These images are important because they show what “pharmaceutical manufacturing” actually meant during the era when Lilly was selling cannabis. One page displays enormous stills and vacuum equipment used to process medicines. Another shows workers operating pill-cutting machinery. Elsewhere there are botanical fields, animal facilities, laboratories, bottling rooms, and specialized buildings.

This was not simply an herb shop that happened to become large. Lilly was constructing an integrated industrial system capable of moving material from the plant or animal through extraction, preparation, testing, bottling, and distribution.

The Bottling Room

The Lilly bottling department makes the transition particularly visible. Workers sit among long tables covered with bottles while shelves of finished preparations rise behind them. The image could almost be mistaken for a food-processing operation until the pharmaceutical context becomes clear.

This is the point at which Cannabis Americana becomes part of a much larger story. Standardizing the plant was useful only if the resulting material could then move through an industrial manufacturing system that reproduced the preparation at scale. Agriculture, extraction, testing, filling, labeling, and distribution increasingly became parts of one controlled chain.

The pharmaceutical corporation was learning how to manage that chain from end to end.

Greenfield: When Lilly’s Laboratory Became a Landscape

Lilly’s expansion eventually reached well beyond its Indianapolis factory. The company developed major biological facilities at Greenfield, Indiana, where the historic Lilly Biological Laboratories were built in 1913–1914. The National Register identifies the complex with the history of medicine and industry, while Lilly’s own materials show the site connected to biological research, animal facilities, and experimental agriculture.

The postcard view of the entrance captures how different this environment looked from the company’s original Pearl Street building. Instead of a cramped urban workshop, the scene resembles an institutional farm or estate, with lawns, mature trees, a gatehouse, distant laboratories, and enough open ground to support biological and agricultural research.

The strongest available documentation does not establish that all Lilly cannabis was grown at Greenfield, so it would be careless to label these images “Lilly’s cannabis farm.” What Greenfield demonstrates instead is the larger infrastructure Lilly was building: pharmaceutical research had become inseparable from managing plants, animals, laboratories, and controlled biological environments.

That matters enormously for the third article in this series, because the horses at Greenfield open another side of the story.

The Horse Stable Was Also a Pharmaceutical Facility

Lilly’s own 1919 handbook contains photographs titled “Stables at the Biological Plant.” They show horses being groomed, horses standing in long rows of stalls, and a procedure labeled “bleeding horse.” The Science History Institute explains that these animals were used in producing antitoxins, including diphtheria antitoxin.

At first glance, cannabis fields and antitoxin horses seem like unrelated subjects. Industrially, however, they belonged to the same emerging pharmaceutical philosophy. A living organism could become part of a controlled production system. The company wanted to know its source, condition, treatment, biological activity, and relationship to the finished medicine.

In one case the organism was a medicinal plant. In another it was a horse producing biological material used in antitoxin manufacture. Both required the company to move beyond chemistry alone and become an institution capable of managing biology itself.

That is one reason Indiana’s pharmaceutical history becomes so interesting around the turn of the century.

Cannabis Was Part of the Mainstream Catalog World

The surviving Lilly handbook also corrects another common misconception: early pharmaceutical companies did not divide their products according to the categories modern consumers would expect. Their catalogs contained botanical extracts, pills, capsules, animal-derived biological products, compounds now considered toxic, narcotics, vaccines, tonics, and medicines whose status changed dramatically during the twentieth century.

Cannabis belonged inside this mixed pharmaceutical universe.

The 1919 handbook is particularly useful because it preserves this world before later regulation, synthetic chemistry, antibiotics, and twentieth-century drug policy reorganized the boundaries of respectable medicine. A physician or pharmacist browsing such a catalog was looking at the output of an industry still partly rooted in nineteenth-century materia medica while rapidly becoming a modern industrial science.

Cannabis stood on that boundary.

The Industrial Meaning of Cannabis Americana

The name Cannabis Americana therefore deserves to be taken seriously. The word Americana did not simply mean that an American company had attached its label to an imported drug. It represented the attempt to create an American-grown, experimentally evaluated, pharmacologically standardized alternative to imported cannabis.

That project followed an increasingly familiar industrial sequence. Manufacturers selected plant material, brought cultivation under greater supervision, experimented with varieties, created extracts, evaluated their effects, standardized the resulting preparation, and placed a corporate guarantee on the bottle.

This was a significant change in who held authority over medicine. The earlier pharmacist depended heavily upon experience, knowledge of suppliers, and inspection of crude drugs. The pharmaceutical corporation increasingly asked the physician and pharmacist to trust the company’s cultivation standards, laboratories, quality-control systems, and brand.

Cannabis was one of the plants through which that transfer of authority took place.

Then Cannabis Became “Marihuana”

The pharmaceutical story did not continue indefinitely. During the early twentieth century, the cultural language surrounding cannabis changed substantially. Pharmaceutical companies continued using words such as cannabis, Cannabis sativa, Cannabis indica, tincture, and fluid extract, while the word marihuana became increasingly prominent in newspapers, law enforcement, and political debate.

State restrictions accumulated before the federal Marihuana Tax Act of 1937, and cannabis was eventually removed from the United States Pharmacopeia in 1942. The decline of pharmaceutical cannabis had several causes, including legal restrictions, difficulty with predictable dosing, changing medical preferences, and competition from other drugs. It should not be reduced to a single conspiracy or a single piece of legislation.

What disappeared from popular memory, however, was the industrial history that preceded the prohibition era.

For several decades, companies were not primarily asking how to eradicate cannabis. They were asking how to improve it as a pharmaceutical product.

The Pictures Change the Story

That older history becomes much easier to understand when the photographs are placed beside one another. First comes Colonel Lilly and the tiny Pearl Street laboratory. Then appear the medicinal plant fields, the Parke-Davis cannabis bottle, the Cannabis Americana advertisement, the giant Detroit laboratory, Lilly’s still room and pill department, the pharmaceutical bottling floor, Greenfield’s agricultural landscape, and finally the enormous biological horse stable.

5

Seen together, these are not disconnected curiosities. They show an industry learning to organize living material.

The crop had to be cultivated. The extract had to be manufactured. The potency had to be evaluated. The bottle had to be standardized. The animal had to be maintained. The biological product had to be harvested. The entire system had to generate roughly predictable results at industrial scale.

That is the world in which Eli Lilly became Eli Lilly.

Before Big Pharma Was Primarily Chemical

Modern pharmaceutical imagery tends to focus on molecules, synthetic chemistry, biotechnology, sterile production lines, and enormous research campuses. The earlier pharmaceutical corporation occupied a more visibly biological landscape. It needed gardens, agricultural land, horses, greenhouses, plant collectors, pharmacists, chemists, stills, extraction rooms, test animals, manufacturing departments, and warehouses.

Cannabis makes that older world especially visible because the plant later became culturally separated from “pharmaceutical medicine.” Around 1900, the division was far less obvious. Cannabis was simply one of the difficult biological drugs that manufacturers wanted to understand and control.

Lilly and Parke-Davis did not solve every problem associated with cannabis. The extracts remained imperfect, cannabinoid chemistry was poorly understood, physiological assays were crude by modern standards, and individual responses remained variable. Yet those weaknesses are exactly why Cannabis Americana matters historically.

The companies knew the drug was inconsistent, and their response was to create a system designed to make it less inconsistent.

What Cannabis Americana Really Was

Cannabis Americana was therefore not just an old weed bottle with a famous corporate name printed on it. It was part of a larger American effort to domesticate pharmaceutical production itself.

Imported medicinal plants represented dependence on uncertain supply chains. Domestic cultivation offered control. Variable botanical extracts presented uncertainty. Physiological testing offered a form of measurement. Small drug shops depended upon individual expertise. Industrial manufacturers promised institutional consistency.

Eli Lilly’s history sits squarely inside that transition. The company began in a modest Indianapolis building in 1876 and grew into an organization operating experimental farms, biological laboratories, extraction departments, animal facilities, bottling rooms, and increasingly sophisticated research operations. The surviving 1919 handbook makes that transformation visible page after page.

Cannabis was there during that transition. It appeared in Lilly bottles, in the domestic breeding efforts documented by the Smithsonian, and in the larger pharmaceutical search for standardized botanical medicines. For a period before federal prohibition transformed the public meaning of the plant, one of the futures imagined for cannabis was not the underground market at all.

It was the American pharmaceutical factory.

And the name manufacturers gave that experiment was Cannabis Americana.